BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
Authors:
- 16 October 2025
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (15) , 1544-1547
Abstract
No abstract availableFunding Information
- Boehringer Ingelheim Stiftung
- Lupus Research Alliance
- Else Kröner-Fresenius-Stiftung (2022_EKEA.72)
- Deutsche Forschungsgemeinschaft (CRC/TRR221, CRC/TRR305, CRC1181, CRC1483, FOR2886, GR 5979/2-1, Leibniz Award)
This publication has 5 references indexed in Scilit:
- Teclistamab-Induced Remission in Refractory Systemic Lupus ErythematosusNew England Journal of Medicine, 2024
- BCMA-Targeted T-Cell–Engager Therapy for Autoimmune DiseaseNew England Journal of Medicine, 2024
- Bispecific T cell engager therapy for refractory rheumatoid arthritisNature Medicine, 2024
- Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case studyEuropean Journal of Cancer, 2024
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studyThe Lancet, 2021